RE:RE:RE:RE:RE:RE:RE:Mackie Research comments on Theralase Technologies Inc.Forgot to add this to my previous post on Cold Genesys ...
And some whined about dilution at TLT ... Maybe they were the uninformed after all ...
Oncology costs a lot ... Below is just another of many example where a 3rd round of financing is valued at 22M$US (as Cold Genesys is based in the US).
March 2019 ...
Cold Genesys secures $22M Series C round for oncolytic ... March 2019 ...
But it's not much about dilution than about winning the war that lead you to the biggest market shares.